Research Analysts’ Recent Ratings Updates for Beauty Health (SKIN)

Several brokerages have updated their recommendations and price targets on shares of Beauty Health (NASDAQ: SKIN) in the last few weeks:

• 1/21/2026 – Beauty Health had its price target raised by analysts at TD Cowen from $1.50 to $1.65. They now have a “hold” rating on the stock.
• 1/21/2026 – Beauty Health was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/21/2026 – Beauty Health had its price target raised by analysts at TD Cowen from $1.50 to $1.65. They now have a “hold” rating on the stock.
• 1/14/2026 – Beauty Health had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $1.60 price target on the stock.

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.